Tech Company Inital Public Offerings
Alector IPO
Headquartered in San Francisco, Alector is now a public company.
Transaction Overview
Company Name
Announced On
2/6/2019
Transaction Type
IPO
Amount
$175,750,000
Proceeds Purpose
The company will use the proceeds to advance its pipeline of drug treatment candidates.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
131 Oyster Point Blvd. 600
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
Alector (Nasdaq: ALEC) is combining state-of-the-art antibody technology and recent discoveries in neuroimmunolgy and human genetics to develop novel therapeutics for Alzheimer's disease, other forms of dementia, and mechanistically related neurodegenerative disorders.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Tillman Gerngross
Chief Executive Officer
Arnon Rosenthal
Chief Financial Officer
Calvin Yu
Chief Medical Officer
Robert Paul
VP - Bus. Development
Robert King
VP - Bus. Development
Sabah Oney
VP - General Counsel
Stephanie Yonker
VP - Human Resources
Clare Hunt
VP - Manufacturing
Christian Simonsen
VP - Operations
Omer Siddiqui
VP - R & D
Hua Long
Browse more venture capital transactions:
Prev: 2/6/2019: Aetion venture capital transaction
Next: 2/6/2019: CathWorks venture capital transaction
Share this article
About Database of VC Transactions
We report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs